Rani Therapeutics (RANI) Revenue & Revenue Breakdown
Rani Therapeutics Revenue Highlights
Rani Therapeutics Revenue by Period
Rani Therapeutics Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | - | 100.00% |
| 2022-12-31 | - | -100.00% |
| 2021-12-31 | $2.72M | 488.10% |
| 2020-12-31 | $462.00K | -52.81% |
| 2019-12-31 | $979.00K | - |
Rani Therapeutics generated - in revenue during NA 2023, up 100.00% compared to the previous quarter, and up 0.00% compared to the same period a year ago.
Rani Therapeutics Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-06-30 | - | 100.00% |
| 2024-03-31 | - | -100.00% |
| 2023-12-31 | $2.75M | 100.00% |
| 2023-09-30 | - | 100.00% |
| 2023-06-30 | - | 100.00% |
| 2023-03-31 | - | 100.00% |
| 2022-12-31 | - | 100.00% |
| 2022-09-30 | - | 100.00% |
| 2022-06-30 | - | 100.00% |
| 2022-03-31 | - | -100.00% |
| 2021-12-31 | $-2.72M | 100.00% |
| 2021-09-30 | - | -100.00% |
| 2021-06-30 | $1.96M | 159.39% |
| 2021-03-31 | $756.00K | 260.00% |
| 2020-12-31 | $210.00K | 94.44% |
| 2020-09-30 | $108.00K | 80.00% |
| 2020-06-30 | $60.00K | -27.71% |
| 2020-03-31 | $83.00K | - |
Rani Therapeutics generated - in revenue during Q2 2024, up 100.00% compared to the previous quarter, and up NaN% compared to the same period a year ago.
Rani Therapeutics Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| EYPT | EyePoint Pharmaceuticals | $46.02M | $9.48M |
| SQZ | SQZ Bio | $21.03M | - |
| TCON | TRACON Pharmaceuticals | $12.04M | $100.00K |
| MOLN | Molecular Partners | $7.04M | $2.74M |
| LYRA | Lyra Therapeutics | $1.56M | $598.00K |
| VCNX | Vaccinex | $570.00K | $232.00K |
| CRVS | Corvus Pharmaceuticals | - | - |
| ALXO | ALX Oncology | - | - |
| CABA | Cabaletta Bio | - | - |
| PHVS | Pharvaris | - | - |
| TARA | Protara Therapeutics | - | - |
| VIRX | Viracta Therapeutics | - | - |
| BMEA | Biomea Fusion | - | - |
| TRVI | Trevi Therapeutics | - | - |
| PMVP | PMV Pharmaceuticals | - | - |
| MNPR | Monopar Therapeutics | - | - |
| VINC | Vincerx Pharma | - | - |
| GLUE | Monte Rosa Therapeutics | - | $4.70M |
| SRZN | Surrozen | - | - |
| TNYA | Tenaya Therapeutics | - | - |
| RANI | Rani Therapeutics | - | - |
| TYRA | Tyra Biosciences | - | - |
RANI Revenue FAQ
What is Rani Therapeutics’s yearly revenue?
Rani Therapeutics's yearly revenue for 2023 was $0, representing an increase of 100.00% compared to 2022. The company's yearly revenue for 2022 was $0, representing a decrease of -100.00% compared to 2021. RANI's yearly revenue for 2021 was $2.72M, representing an increase of 488.10% compared to 2020.
What is Rani Therapeutics’s quarterly revenue?
Rani Therapeutics's quarterly revenue for Q2 2024 was $0, a 100.00% increase from the previous quarter (Q1 2024), and a 0% increase year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $0, a -100.00% decrease from the previous quarter (Q4 2023), and a 0% increase year-over-year (Q1 2023). RANI's quarterly revenue for Q4 2023 was $2.75M, a 100.00% increase from the previous quarter (Q3 2023), and a 0% increase year-over-year (Q4 2022).
What is Rani Therapeutics’s revenue growth rate?
Rani Therapeutics's revenue growth rate for the last 3 years (2021-2023) was -100.00%, and for the last 5 years (2019-2023) was -100.00%.